scorecardresearch
Add as a preferred source on Google
Saturday, February 14, 2026
TopicCDSCO

Topic: CDSCO

Health ministry eases drug trial rules. Test licences scrapped, CDSCO approval timelines cut by half

Under earlier rules, drugmakers had to get a test licence from CDSCO to manufacture small quantities of drugs for research, examination or analysis.

Use nimesulide only after exhausting first-line options—expert panel under drug regulator CDSCO

Last year, an ICMR panel even considered recommending all-India ban on popular painkiller amid concerns it could cause liver damage, which could turn life-threatening in some cases.

As CDSCO lifts suspension on eye drops designed to replace reading glasses, makers eye June launch

Doctors caution that the drug should be used only under strong and regular supervision of an ophthalmologist.

No local clinical trial waiver despite change in rules, drugmakers knock on health ministry’s door

Drug regulator through executive order issued last August paved way for direct launch of certain categories of drugs approved in select countries by means of local clinical trials waiver.

Antibiotics launched in India will soon need CDSCO nod as drug resistance emerges as silent killer

In 2019, bacterial antimicrobial resistance killed between 3 lakh and 10.4 lakh people in India, according to a Lancet report.

Why a govt-appointed panel has recommended a complete ban on popular painkiller nimesulide

First launched in Italy in 1985, Nimesulide is available in India under brand names like Nimuwin, Nimutab, Nimopen, Nisulid, Nimdase, Nodard Plus, Nicip, Nimcap, Nicip-P and Nimupain.

Govt says no plan to ban heartburn drug ranitidine, carcinogenic impurities within safe limits

In 2019, evidence showed that an impurity in drug degrades over time to form probable carcinogenic compound. Ranitidine is sold as heartburn medicine under names Rantac, Aciloc & Zinetac.

Drug regulator considers making central nod mandatory for all antibiotics in India, even existing ones

This new proposal, being considered by CDSCO, comes in response to concerns over antimicrobial resistance emerging as a massive public health challenge across the globe, including in India.

India has a substandard, fake drugs problem. Lack of recall law, scrutiny is making matters worse

Underlining need for more accountability, experts also stress that govt data does not include fixed dose combination drugs, which account for over 40% of drugs sold in India.

Eye drop’s claim to replace glasses cost it the launch & sale nod. The controversy & safety concerns

Regulatory approval to Entod Pharma for PresVu, meant to treat presbyopia, was revoked as the firm marketed it as a 'replacement for reading glasses' & due to possible health risks.

On Camera

How the RSS dialogue on caste changed over 100 years. Sangh and its ‘samajik samrasta’

Contrary to naysayers, the RSS practices what it preaches. It is closer to the Gandhian teaching of improving the individual morally and spiritually to change the external environment.

7 lakh jobs created, Rs 50 lakh-cr investments bagged, says UP CM. Oppn flags MoU-reality gap

CM Yogi Adityanath claims that from being called a ‘bimaru’ state, UP is now among the top-3 economies in India. The 2026 Budget session of the UP assembly is currently underway.

Australian amphibian aircraft firm eyes Indian civil & military market, ties up with Apogee Aerospace

Aligning with India's push to promote inter-coastal air connectivity, Apogee has ordered 15 seaplanes in a deal valued at Rs 3,500 crore.

The new Great Game—Trump’s playing for time, China for leverage & India for wiggle room

This is the game every nation is now learning to play. Some are finding new allies or seeing value among nations where they’d seen marginal interest. The starkest example is India & Europe.